Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the ‘Central neuropathic pain in adults’ indication extension.
Clinical Benefit
| Substantial |
The actual benefit of LYRICA in the treatment of central neuropathic pain in adults is substantial. |
Clinical Added Value
| no clinical added value |
Lyrica does not provide any improvement in actual benefit (IAB level V) over the usual management of central neuropathic pain in adults. |
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
WTqQPJSUNWhReM3k
